Company news

Verastem, Inc. news in 2022

Verastem, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Verastem Oncology Appoints Rob Gagnon to Board of Directors

December 14, 2022

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 2, 2022

Verastem Oncology Appoints Anil Kapur to Board of Directors

October 19, 2022

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

October 3, 2022

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 7, 2022

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer

June 5, 2022

Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer

May 17, 2022

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 8, 2022

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

March 27, 2022

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors

March 27, 2022

Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board

March 23, 2022

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

January 10, 2022

Decks in 2022